HCM Q2 2022 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$202M+166.5% YoY

Gross Profit

$65M32.0% margin

Operating Income

-$197M-97.4% margin

Net Income

-$163M-80.6% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+100.0%

Cash Flow

Operating Cash Flow

-$90M

Free Cash Flow

-$106M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$342M

Stockholders' Equity

$800M

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$202M	$76M	+166.5%
Gross Profit	$65M	$17M	+269.9%
Operating Income	-$197M	-$81M	-144.3%
Net Income	-$163M	-$77M	-110.3%

Revenue Segments

Product

$137M68%

Commercialization Services

$22M11%

Other Collaboration Licensing Revenue

$15M7%

Other Collaboration Royalties Revenue

$14M7%

Collaboration Research And Development

$12M6%

Research And Development Services

$263,0000%